CD19 and hematopoietic and lymphoid cell neoplasm: For instance, the phase 1/2 study NCT03056339 explored the efficacy of anti-CD19 CAR-NK cells, derived from cord blood, in 11 patients with relapsed or refractory CD19+ hematologic cancers (93).